Amylyx Pharmaceuticals, Inc. - Common Stock (AMLX)
3.0100
+0.0100 (0.33%)
Amylyx Pharmaceuticals is a biotechnology company focused on the development of innovative therapeutics for neurodegenerative diseases
The company aims to address significant unmet medical needs, particularly in conditions such as amyotrophic lateral sclerosis (ALS) and Alzheimer’s disease, through its proprietary drug candidates that target underlying biological processes. By leveraging scientific expertise and advanced research techniques, Amylyx is committed to delivering effective treatment options that enhance the quality of life for patients affected by these challenging conditions.
Amylyx Pharmaceuticals acquired avexitide from Eiger BioPharmaceuticals Inc. for $35.1 million. Avexitide, a GLP-1 receptor antagonist, ready for Phase 3 trial for post-bariatric hypoglycemia and congenital hyperinsulinism.
Amylyx's AMX0035 data in treating Wolfram syndrome, with interim data indicating positive effects on diabetes progression, visual decline, and overall disease burden. Safety profile consistent.
Seelos Therapeutics updates Phase 2/3 HEALEY ALS trial with SLS-005, showing potential efficacy in subgroup analysis. Explore the latest data on ALS treatment with SLS-005."
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite dipping around 0.5% on Friday. The Dow traded up 0.27% to 38,894.21 while the NASDAQ fell 0.51% to 16,190.52. The S&P 500 also fell, dropping, 0.20% to 5,146.8.
Shares of Marvell Technology, Inc. (NASDAQMRVL) fell sharply during Friday’s session after the company reported fourth-quarter financial results and issued weak Q1 guidance.
U.S. stocks traded mixed midway through trading, with the Dow Jones index gaining around 80 points on Friday. The Dow traded up 0.21% to 38,874.05 while the NASDAQ fell 0.42% to 16,204.26. The S&P 500 also fell, dropping, 0.13% to 5,150.72.
